About Orthogonal Biologics
Orthogonal Biologics is a company based in United States founded in 2020 was acquired by Cyrus Biotechnology in December 2021. Orthogonal Biologics operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Cyrus Biotechnology
(Dec 06, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Orthogonal Biologics
Detailed funding history for Orthogonal Biologics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Orthogonal Biologics
Orthogonal Biologics has secured backing from 1 investor. Prominent investors backing the company include Cyrus Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cloud-based protein-modeling software is developed for drug discovery.
|
Locked | Locked | Locked |
Investor details for Orthogonal Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orthogonal Biologics
Investment portfolio details for Orthogonal Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orthogonal Biologics
Detailed financials for Orthogonal Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orthogonal Biologics Comparisons
Peer comparison for Orthogonal Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orthogonal Biologics
Orthogonal Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
R&D focused on manufacturing of drugs for multiple therapeutic areas
|
|
| Locked | Locked | Locked |
CDMO offering drug and biologics development services
|
|
| Locked | Locked | Locked |
Selective Wnt agonists are developed for human tissue regeneration.
|
|
| Locked | Locked | Locked |
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
|
| Locked | Locked | Locked |
Drug research, development, testing, and consulting services are provided.
|
|
| Locked | Locked | Locked |
Provides contract research, development, and manufacturing services for biologic drugs.
|
Detailed competitors of Orthogonal Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orthogonal Biologics
Complete news archive for Orthogonal Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orthogonal Biologics
Orthogonal Biologics was founded in 2020.
Orthogonal Biologics is headquartered in United States.
Erik Procko is the current CEO of Orthogonal Biologics.
Orthogonal Biologics was founded in 2020 and is based in the United States. Operations focus on the biotechnology sector, where manufacturing and research services for protein drugs are offered. These services support drug development processes, including production and scientific investigation. The company is led by CEO Erik Procko, with activities centered on advancing biologic therapies through specialized expertise.
Orthogonal Biologics has 1 investor. Key investors include Cyrus Biotechnology.